Etidocaine HCl
CAS: 36637-19-1
Rif. 3D-FE23187
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione | ||
| 250mg | Fuori produzione |
Informazioni sul prodotto
- N-(2,6-dimethylphenyl)-2-(ethylpropylamino)butanamide hydrochloride(±)-N-(2,6-dimethylphenyl)-2-(ethylpropylamino)butanamide monohy drochlorideDuranest
- 1-[(2,6-dimethylphenyl)amino]-N-ethyl-1-oxo-N-propylbutan-2-aminium chloride
- Butanamide, N-(2,6-dimethylphenyl)-2-(ethylpropylamino)-, hydrochloride (1:1)
- Butanamide, N-(2,6-dimethylphenyl)-2-(ethylpropylamino)-, monohydrochloride
- Duranest
- Duranest hydrochloride
- Etidocaine Hydrochloride
- N-(2,6-dimethylphenyl)-2-[ethyl(propyl)amino]butanamide
- W 19053
Etidocaine HCl is a local anesthetic with a rapid onset of action. It binds reversibly to sodium channels in the nerve membrane, blocking the passage of sodium ions and thereby preventing neural conduction. Etidocaine HCl has been shown to have high plasma drug concentrations, which are sustained for up to 12 hours. The clinical properties of this drug are similar to those of bupivacaine HCl, but it is less viscous and more biocompatible with tissue than bupivacaine HCl. Etidocaine HCl has been found to be safe and effective in animals as well as humans. Etidocaine HCl has been shown to significantly reduce clotting time in patients when compared with untreated control subjects. This drug does not cause significant toxicity in humans or animals, and does not inhibit fibrinogen synthesis or blood coagulation.
